Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 15/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482276 | 0.90 | NR1H4 (0.43) | GLP1RPDE10AHTR1ACYP2C8KCNH2 | |
| SCHEMBL1482050 | 0.89 | NR1H4 (0.44) | GLP1RPDE10AHTR1ACYP2C8KCNH2 | |
| SCHEMBL1482910 | 0.89 | GLP1R (0.39) | GLP1RPDE10AHTR1ACYP2C8KCNH2 | |
| SCHEMBL1482279 | 0.88 | GLP1R (0.42) | GLP1RPDE10AHTR1ACYP2C8KCNH2 | |
| SCHEMBL1482694 | 0.85 | NR1H4 (0.37) | GLP1RPDE10AHTR2CSLC6A4 | |
| SCHEMBL1482409 | 0.83 | NR1H4 (0.41) | GLP1RHTR2CSLC6A4 | |
| SCHEMBL1482189 | 0.82 | NR1H4 (0.42) | GLP1RHTR2CSLC6A4 | |
| SCHEMBL1482669 | 0.81 | NR1H4 (0.41) | GLP1RHTR2CSLC6A4 | |
| SCHEMBL1482738 | 0.81 | HTR2C (0.42) | GLP1RHTR2CSLC6A4 | |
| SCHEMBL1483043 | 0.81 | NR1H4 (0.37) | GLP1RKCNH2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2483247-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011039130-A1 | NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-07 | — | — | WO | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | GLP1R 451/4885PDE10A 780/4885HTR1A 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.